IGF1-LR3 1mg For Bodybuilding CAS:143045-27-6

    What is IGF-1 LR3?

    ●Core Identity: IGF-1 LR3 is a recombinant, structurally modified analog of naturally occurring Insulin-like Growth Factor 1 (IGF-1).

    ●The "LR3" Modification: This is the key differentiator. The modification involves:

    ○N-terminal Arginine Substitution: Replacing the first 3 amino acids (Glu-Pro-Glu) with an Arginine (R) residue.

    ○13-amino Acid Extension: Adding a 13-amino acid peptide sequence to the C-terminus.

    ●Purpose of Modification: These alterations serve two critical functions:

    1.Reduced Binding Affinity for IGF Binding Proteins (IGFBPs): Natural IGF-1 circulates tightly bound (up to 99%) to IGFBPs, significantly limiting its bioavailability and biological activity. The LR3 modification drastically reduces this binding, vastly increasing the amount of free, biologically active IGF-1 available to interact with receptors.

    2.Extended Half-Life: The reduced binding to IGFBPs directly contributes to a dramatically prolonged half-life compared to endogenous IGF-1 or IGF-1 DES (discussed later).  

    1.Superior Bioavailability: The reduced IGFBP binding is its defining feature, leading to significantly higher levels of active, unbound IGF-1 in circulation compared to the natural hormone or other analogs when administered exogenously.

    2.Prolonged Half-Life: Estimated at 20-30 hours post-subcutaneous injection. This contrasts sharply with natural IGF-1 (minutes) or IGF-1 DES (approx. 20-30 minutes). This allows for convenient once-daily dosing.

    3.Systemic Action: Unlike IGF-1 DES, which is often (misguidedly) promoted for localized "site growth" effects due to its ultra-short half-life requiring immediate binding, IGF-1 LR3's long half-life ensures its effects are primarily systemic. It circulates widely, affecting multiple tissues.

    4.Receptor Specificity: Primarily binds to the IGF-1 Receptor (IGF-1R), which mediates its primary anabolic and metabolic effects. Binding affinity for the Insulin Receptor (IR) is significantly lower, though not negligible at higher concentrations.

    5.Anabolic Potency: Its ability to potently stimulate the IGF-1R systemically makes it a powerful anabolic agent, acting on muscle, bone, and connective tissue.

    IGF-1 LR3's primary appeal lies in its potent anabolic signaling:

    1.Hyperplasia & Hypertrophy Synergy:

    ○Satellite Cell Activation: IGF-1 is a master regulator of satellite cells (muscle stem cells). LR3 potently stimulates their proliferation and differentiation, potentially leading to hyperplasia – an increase in the actual number of muscle fibers. This is distinct from and complementary to hypertrophy (increase in fiber size).

    ○Protein Synthesis Boost: Via the mTOR pathway, IGF-1 LR3 significantly upregulates muscle protein synthesis rates.

    ○Anti-Catabolic Effects: Inhibits key pathways involved in muscle protein breakdown.

    2.Enhanced Nutrient Partitioning:

    ○Glucose Uptake: Potently stimulates glucose uptake into muscle cells (similar to insulin, though via distinct but overlapping pathways), creating a highly anabolic intracellular environment and improving glycogen storage.

    ○Amino Acid Transport: Facilitates increased transport of amino acids into muscle cells, providing the raw materials for protein synthesis.

    3.Connective Tissue & Joint Support: Stimulates collagen synthesis in tendons, ligaments, and cartilage. This is crucial for athletes subjecting their joints to heavy loads, potentially aiding injury resilience and recovery.

    4.Fat Loss Potential: While not a primary fat burner, its metabolic effects (increased glucose uptake/utilization, potential increase in metabolic rate) can contribute to improved body composition, particularly when combined with diet and training.

    5.Recovery Acceleration: By promoting satellite cell activity, protein synthesis, and nutrient shuttling, IGF-1 LR3 can significantly accelerate recovery between intense training sessions.

    ●Significant Lean Muscle Mass Gains: Primarily through the combined effects of hypertrophy and potential hyperplasia.

    ●Improved Muscle Density and Hardness: Resulting from enhanced glycogen storage and nutrient partitioning.

    ●Reduced Body Fat Percentage: Secondary benefit from metabolic enhancements.

    ●Enhanced Recovery Capacity: Allows for more frequent, intense training.

    ●Potential Joint and Tendon Strengthening: Via increased collagen synthesis.

    ●Synergy with Other Compounds: Can be effectively stacked with AAS, insulin (with extreme caution), and GH for amplified effects, though complexity and risk increase dramatically.

    ●Range: Dosing typically falls between 20mcg and 100mcg per day. 50-80mcg/day is a common effective range for experienced users.

    ●Start Low: Always begin at the lower end (e.g., 20-40mcg/day) to assess individual tolerance.

    ●Titration: Gradually increase by 10-20mcg every few days only if well-tolerated and seeking stronger effects. Higher doses (>80-100mcg) exponentially increase the risk of side effects, particularly hypoglycemia and potential organ growth.

    ●Administration: Subcutaneous injection is standard. Due to systemic effects, site rotation is for comfort/avoiding lipoatrophy, not targeting specific muscles. Reconstituted peptide requires refrigeration.

    ●Timing: Once daily. Timing relative to training or nutrition is debated; common protocols include pre-workout (for nutrient shuttling), post-workout (for recovery), or before bed (aligning with natural GH pulse). Consistency is likely more important than absolute timing.

    ●Duration: Typically 4 to 8 weeks. Longer cycles increase the potential for desensitization (receptor downregulation) and organomegaly risks. Short, targeted cycles are generally preferred.

    ●Frequency: Often used in 1-2 cycles per year, separated by significant off-periods (e.g., 4-6 months minimum) to mitigate long-term risks and allow receptor sensitivity to recover.

    ●Stacking:

    ○With GH: A synergistic combination, as GH stimulates endogenous IGF-1 production. LR3 provides direct, potent IGF-1R activation independent of GH fluctuations.

    ○With AAS: Provides complementary anabolic pathways. AAS enhance the anabolic response to IGF-1.

    ○With Insulin: EXTREME CAUTION REQUIRED. Potent synergy for nutrient shuttling and anabolism, but drastically increases hypoglycemia risk and potential organ growth. Only for highly experienced users with meticulous protocols and glucose monitoring.

    ●Post-Cycle Therapy (PCT): Crucially different from AAS PCT. IGF-1 LR3 does not suppress the hypothalamic-pituitary-testicular axis (HPTA). Therefore, traditional SERM/AI-based PCT is unnecessary and inappropriate. Focus shifts to:

    ○Metabolic Reset: Gradual reduction in calories, particularly carbohydrates, as insulin sensitivity may be heightened.

    ○Receptor Resensitization: Time off is the primary method. Certain supplements (Berberine, Omega-3s) may support insulin sensitivity and metabolic health.

    ○Health Monitoring: Blood work (fasting glucose, lipids, kidney/liver markers) to assess recovery baseline.

    ○Supporting Natural IGF-1: Optimize sleep, nutrition (especially protein), and manage stress post-cycle.

    ●Approximately 20-30 hours. This is its defining pharmacokinetic characteristic.

    ●Implications:

    ○Once-Daily Dosing: Sufficient for stable systemic exposure.

    ○Steady State: Takes several days (4-5 half-lives) to reach steady-state concentrations.

    ○Sustained Effect: Provides continuous anabolic signaling throughout the day, unlike shorter-acting analogs.

    ○Clearance: Primarily renal. Impaired kidney function is a contraindication.

    1.Hypoglycemia: The MOST COMMON and ACUTE risk. IGF-1 LR3 potently lowers blood glucose. Symptoms: sweating, tremor, anxiety, dizziness, weakness, confusion, loss of consciousness. Must consume sufficient carbohydrates (especially around injection time), monitor blood glucose, and have fast-acting sugar on hand. Diabetics or those with hypoglycemia unawareness should avoid.

    2.Organ Enlargement (Organomegaly): A serious long-term risk. IGF-1 receptors are present in internal organs (heart, kidneys, liver, spleen). Chronic supraphysiological dosing can lead to irreversible growth of these organs, particularly the heart (cardiomegaly), increasing risk of cardiac dysfunction and failure.

    3.Edema (Water Retention): Common, caused by fluid shifts related to glucose uptake and sodium retention. Usually manageable, but can mask definition.

    4.Numbness/Tingling (Paraesthesia): Often reported in hands and feet, possibly related to nerve sensitivity or fluid shifts. Usually transient.

    5.Joint Aches/Pains: Can occur, potentially due to rapid connective tissue changes or fluid retention.

    6.Increased Cancer Risk (Theoretical): IGF-1 is a potent mitogen. While no direct causal link in healthy adults is proven, promoting cell proliferation systemically is a theoretical risk factor, especially if pre-cancerous cells exist. Absolute contraindication with active cancer or strong family history.

    7.Acromegaly-like Symptoms (Chronic High Dose): Enlarged hands/feet, jaw protrusion, coarsening of facial features – results from excessive systemic IGF-1 stimulation over very long periods.

    8.Insulin Resistance: Paradoxically, chronic high doses may contribute to insulin resistance over time, though acute effects enhance insulin sensitivity. Manage with diet and cycle duration.

    9.Lipoatrophy at Injection Sites: Possible with repeated injections in the same spot. Rotate sites.

   10.Headaches & Fatigue: Reported by some users.

    ●DES: Unmodified IGF-1 with the first 3 amino acids removed. Extremely short half-life (20-30 min). Requires immediate binding locally after injection. The "site growth" claim is largely anecdotal and scientifically dubious; systemic effects still occur rapidly. Requires multiple daily injections (pre/post workout).

    ●LR3: Modified for reduced IGFBP binding and long half-life (20-30 hrs). Systemic action is primary. Once-daily dosing. More practical and consistent for overall anabolism and recovery.

Trade names	Long R3-IGF-1; IGF-1 Long R3
CAS	143045-27-6
Molar mass	9117.60
Formula	C400H625N111O115S9
Purity	Above 98%
Apprarance	1mg/vial,Lyophilized powder

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                   

 

    IGF-1 LR3 1mg is not a beginner's compound. It represents a powerful pharmacological intervention into the fundamental growth machinery of the body. Its potential for significant muscle gain, enhanced recovery, and improved body composition is counterbalanced by substantial risks, particularly hypoglycemia and the insidious threat of organomegaly with misuse or prolonged use.

    Successful and safer implementation demands:

    ●Thorough Research: Beyond forums – understand the molecular biology.

    ●Medical Consultation & Blood Work: Pre, during (glucose!), and post-cycle.

    ●Conservative Dosing & Cycle Length: Start low, go slow, keep cycles short.

    ●Meticulous Hypoglycemia Management: Never underestimate this risk.

    ●Realistic Expectations: It's a potent tool, not magic. Diet and training remain paramount.

    ●Long-Term Health Perspective: Prioritize health over short-term gains. The potential consequences of organ enlargement are severe and irreversible.

    Used judiciously, strategically, and with extreme caution, IGF-1 LR3 can be a transformative agent in advanced bodybuilding. Used recklessly, it poses significant dangers. The choice hinges on a profound respect for its power and a commitment to minimizing risk.

Hot Tags: igf1-lr3 1mg for bodybuilding cas:143045-27-6, China igf1-lr3 1mg for bodybuilding cas:143045-27-6 manufacturers, suppliers, factory